title: Network biology in development of monoclonal antibody therapeutics.
abstract: Monoclonal antibodies (mAbs) are large glycoproteins that recognize and remove/neutralize a specific target. Inflammation and inflammatory diseases are often treated with mAb-based therapeutics. Mathematical modeling is widely used in development of mAbs. Bioinformatics and structural modeling is used for humanization of mAbs and PK/PD modeling is extensively used in preclinical and clinical development. The objective of this commentary is to introduce systems biology-based modeling that can accelerate and improve development of mAbs.
authors.affiliation: Merck Research Laboratories, 901 S. California Avenue, Palo Alto, CA 94304, USA . Electronic address: ayse.meric.ovacik@merck.com.
authors.forename: Ayse Meric
authors.initials: AM
authors.lastname: Ovacik
mesh_terms: D000911:Antibodies, Monoclonal; D055808:Drug Discovery; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D008962:Models, Theoretical; D049490:Systems Biology
chemical_list: D000911:Antibodies, Monoclonal
keywords: Drug development; Monoclonal antibodies; Network biology; Proteomics; Systems biology; Transcriptomics